Wealthfront Advisers’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$15.4M Buy
80,105
+64,484
+413% +$6.95M 0.03% 198
2026
Q2
$1.09M Sell
15,621
-4,623
-23% -$239K ﹤0.01% 706
2026
Q1
$1.03M Buy
20,244
+6,508
+47% +$304K ﹤0.01% 711
2025
Q4
$405K Sell
13,736
-3,712
-21% -$101K ﹤0.01% 861
2025
Q3
$451K Sell
17,448
-1,439
-8% -$40.1K ﹤0.01% 834
2025
Q2
$521K Sell
18,887
-12,131
-39% -$319K ﹤0.01% 786
2025
Q1
$879K Buy
31,018
+18,268
+143% +$648K ﹤0.01% 684
2024
Q4
$530K Sell
12,750
-161
-1% -$7.7K ﹤0.01% 771
2024
Q3
$863K Sell
12,911
-9,172
-42% -$842K ﹤0.01% 672
2024
Q2
$2.62M Buy
22,083
+8,081
+58% +$1.02M 0.01% 419
2024
Q1
$1.49M Buy
14,002
+9,003
+180% +$907K 0.01% 539
2023
Q4
$497K Buy
+4,999
New +$420K ﹤0.01% 719
2023
Q2
– Sell
-16,804
Closed -$2.58M – 836
2023
Q1
$2.58M Sell
16,804
-8,005
-32% -$1.32M 0.01% 358
2022
Q4
$4.46M Buy
24,809
+15,666
+171% +$2.56M 0.02% 223
2022
Q3
$1.08M Sell
9,143
-6,162
-40% -$935K 0.01% 473
2022
Q2
$2.19M Sell
15,305
-12,877
-46% -$1.84M 0.01% 357
2022
Q1
$4.86M Sell
28,182
-5,519
-16% -$929K 0.02% 213
2021
Q4
$8.56M Buy
33,701
+3,815
+13% +$1.12M 0.04% 117
2021
Q3
$11.5M Buy
29,886
+24,157
+422% +$8.91M 0.05% 73
2021
Q2
$1.35M Buy
+5,729
New +$1.02M 0.01% 382

Other funds holding MRNA

Wealthfront Advisers's MRNA Position: Q3 2026 in Review

Wealthfront Advisers increased its Moderna (MRNA) stake by 413% in Q3 2026, buying an estimated $6.95M and bringing the position to 80,105 shares worth $15.4M. The position accounts for 0.03% of the portfolio, ranked #198.

Wealthfront Advisers first reported a position in MRNA in Q2 2021 and has held it in 20 quarters since. 1,048 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Wealthfront Advisers held 80,105 shares of Moderna worth $15.4M as of Q3 2026.
  • Wealthfront Advisers bought 64,484 Moderna shares in Q3 2026, an estimated $6.95M.
  • Moderna made up 0.03% of Wealthfront Advisers's portfolio in Q3 2026, its #198 holding.
  • Wealthfront Advisers first reported a position in Moderna in Q2 2021 and has held it in 20 quarters since.
  • 1,048 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Wealthfront Advisers's 13F filing for Q3 2026, filed 9 Nov 2026.